Saudi Arabia Aims To Localise 90% Of Its Insulin Need

Saudi Arabia Aims To Localise 90% Of Its Insulin Need

The Minister of Industry and Mineral Resources Bandar Al-Khorayef confirmed that the Ministry aims to localise between 80% and 90% of Saudi Arabia’s need for insulin.

Al-Khorayef made the remarks, on Sunday, while participating in the Global Health Forum in Riyadh. He indicated that the Ministry is keen to attract qualitative investment in the pharmaceutical, and healthcare sectors, as well as to export to foreign markets.

Since the establishment of the Treatments Localisation and Development Committee in 2020, it has received more than 1,000 pharmaceutical preparations from several agencies. There were more than 200 priority treatments counted, constituting approximately 40% of the total purchases of government health agencies, which amount to approximately SR14 billion.

Al-Khorayef said that the Vaccines and Biopharmaceuticals Industry Committee came to complete the Treatments Localization and Development Committee, as well as to include a number of ministers and stakeholders.

The Vaccines and Biopharmaceuticals Industry Committee is working on studying and localising a number of vital pharmaceutical preparations, including vaccines, insulin, plasma derivative products, as well as all medications and biosimilars, whose localization rate, according to the prepared strategies, will exceed more than 70%.

The number of pharmaceutical factories registered in the Industry and Mineral Resources Ministry reached 84, of which, 48